On 7th July 2021, the German Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte – BfArM) launched the first sale of cannabis exclusively for medical purposes from cultivation in Germany.
Genetically modified microbes are being fermented in breweries, today, to produce cannabinoids. The combination of genetic engineering and fermentation is called “Precision Fermentation” (PF). The resulting Precision-Fermented Cannabinoids (PFCs) can be sold as isolates, blended with terpenes and flavonoids into pseudo-extracts, and soaked into cheap hempseed flower biomass to make pseudo-marijuana flower. These PFC-based products are likely to satisfy those who want to treat their medical conditions (or get high) inexpensively—that is, everyone except connoisseurs.
The delta-8 -tetrahydrocannabinol (delta-8-THC) trend has emerged as a solution to this oversupply of CBD biomass. An interesting chemical property of CBD meant that chemists could convert the unwanted CBD into isomers of THC
Much of the cannabis industry we see today is based around just two of the 1000+ phytochemicals that reside in cannabis: cannabidiol (CBD); and tetrahydrocannabinol (THC). All progress thus far has been made through a primary focus on these two phytocannabinoids, just a tiny fraction of the plant’s potential. CBD is just the tip of the iceberg.
As we enter the critical stage in our fight against the COVID-19 pandemic and its lingering effects on the world’s economy, business operations, and our daily lives, it is encouraging to see that the healthcare industry, including innovation and investments in this area, both globally and in Thailand, remains strong and resilient despite the pandemic. This outlook on growth and innovation also applies in the area of cannabis.